Zydus Lifesciences Limited, a leading global lifesciences company, has recently inked a non-exclusive patent licensing deal with Takeda Pharmaceutical Company to introduce Vonoprazan, a novel Potassium Competitive Acid Blocker (P-CAB), in the Indian market under the brand name Vault®.

Gastroesophageal Reflux Disease (GERD) affects a significant portion of the Indian population, with a prevalence of 15.6% as reported in the Indian Journal of Gastroenterology, 2021. Factors contributing to GERD include age, body mass index (BMI), diet, tea/coffee intake, tobacco, and alcohol consumption.

Zydus, known for pioneering innovative treatments for GERD such as Pantodac® (Pantoprazole), Happi® (Rabeprazole), and Ocid® (Omeprazole), aims to expand its therapeutic portfolio with the launch of Vault®. Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Ltd., expressed enthusiasm about this development, highlighting the company's commitment to providing advanced healthcare solutions across India.

Vault® operates through a unique mechanism by inhibiting the binding of potassium ions to H+K+ ATPase (proton pump) in the stomach's parietal cells, thereby effectively reducing both basal and stimulated gastric acid secretion. The Drug Controller General of India (DCGI) has approved Vonoprazan for treating Reflux esophagitis and other Acid Peptic Disorders (APD) among adults in the country.

This strategic move not only underscores Zydus' dedication to addressing prevalent health conditions in India but also marks a significant addition to its comprehensive gastro therapeutic offerings. With its established legacy in gastrointestinal therapies and a focus on patient-centric care, Zydus continues to innovate and enhance access to cutting-edge treatments for acid peptic disorders nationwide.